antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated in an ongoing global Phase 1a/1b clinical trial (NCT06179069 ...

VAX-24 Mid dose met Phase 2 non-inferiority criteria for 20 of 24 serotypes and showed strong immune responses across all doses. Full post-dose 4 booster data is expected by late 2025, with a ...

European Union country-level data have demonstrated that the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine) ...

European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults EC decision ...

CHENGDU, China, March 25, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the ...

This more straightforward method makes M6P antibody conjugations a more favorable, biologics-based option to achieve targeted protein degradation in lysosomes. Ultimately, these antibody ...

The two licenses span 19,000 square kilometers (7,335.94 square miles). Challenger Energy says conjugate margin discoveries in Africa offer hope for similar potential in Uruguayan plays.

The pneumococcal conjugate vaccines that were studied were the PCV10 (GSK) and PCV13 (Pfizer). The saccharide in PCV10 is conjugated to nontypable Haemophilus influenzae protein D, tetanus toxoid ...

The phase III clinical trials of Biological E’s (BE)’s 14-Valent Pneumococcal Conjugate Vaccine (PCV), Pneubevax14 (BE-PCV-14) conducted in paediatric population of six to eight week age g ...

the company’s global next-generation antibody-drug conjugate (ADC) program. The preclinical profile of ZL-1310 will be the focus of a poster presentation at the European Lung Cancer Congress ...

(RTTNews) - SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, 'GBP410' also known as SP0202 ...